Pre-Seed Extension

Published:
May 11, 2021

BioLoomics closed a $575,000 round of pre seed extension funding on May 11, 2021. The funds were contributed by private investors, including several investors who participated in the pre-seed round. BioLoomics will use the seed funding to apply the technology that was refined in the pre-seed period, expand the team, continue producing industry leading biosensors, and begin developing biosensing biologics. 

The VariVolve platform leverages evolution in a microscope to produce novel biosensors for high throughput screening and to create drug candidates with improved target specificity. We test millions of protein designs for a targeted activity in hours, enabling efficient mining of the vast chemical space of protein designs. BioLoomics uses whole, intact cells as test vessels that capture complex drug behavior which is not attainable in conventional assays.

The team at BioLoomics is beyond grateful for the support of our investors. We are eagerly looking toward a future with biosensing biologics available to treat many different diseases and conditions.

BioLoomics is on a mission to tackle disease with smart protein drugs. If you have a difficult to solve problem in drug discovery, or require higher quality assays for your search, contact us. 

Written by

View More News

BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs

October 15, 2024

BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs

Former CSO of Trilo Therapeutics and Research Fellow atAbbVie joins to lead BioLoomics’ pipeline and combine lysosome targetingantibodies with ADCs

October 15, 2024
View News Article

Backed by former Google CEO’s VC, a Colorado biotech hatches platform to evolve degraders

June 13, 2024

Backed by former Google CEO’s VC, a Colorado biotech hatches platform to evolve degraders

BioLoomics’ goal is to make a degrader from an antibody in one month

June 13, 2024
View News Article

BioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading Antibodies

June 13, 2024

BioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading Antibodies

Our mission is to make safer, more effective cancer therapeutics.

June 13, 2024
View News Article

Pre-Seed Extension

June 13, 2024

Pre-Seed Extension

BioLoomics closed a $575,000 round of pre seed extension funding on May 11, 2021..

June 13, 2024
View News Article

OEDIT Grant Award

June 13, 2024

OEDIT Grant Award

The Colorado OEDIT provides funding opportunities to small businesses in fourteen industries...

June 13, 2024
View News Article

BioLoomics Closes $600k Pre-Seed Round to Launch Biosensing Drug Discovery Platform

June 13, 2024

BioLoomics Closes $600k Pre-Seed Round to Launch Biosensing Drug Discovery Platform

We are excited to announce that on May 30, 2019, BioLoomics closed a $600,000 pre-seed round...

June 13, 2024
View News Article
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.